Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Quotes

Analysis

Analyst Ratings

News

Press Releases

Twitter

Media Mentions

Ownership

Earnings

Immunomedics, Inc. (IMMU) 0.00 0.13
Price Open:4.22Day's Range:0.00000 - 4.52000
Price Close:4.3052wk Range:0.00000 - 4.52000
Price Day Change:0.13Volume:965,072
Price % Change:3.02Market Cap:366.4M
Bid:3.64000PE Ratio:0
Ask:0.00000EPS Diluted:-0.16
Trade IMMU NOW!

The Latest On IMMU

Immunomedics Says UCB Offers New Results from Phase 2B Open-Label Extension Study of Epratuzumab in SLE 6/13/13 8:46am
Immunomedics Announces Combo of 90Y-Epratuzumab-Veltuzumab is Active in Non-Hodgkin Lymphoma 6/11/13 8:38am
90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOP 6/10/13 4:35pm
Immunomedics Announces New Novel Dual System for Tumor Detection, Imaging 6/10/13 8:19am
Afternoon Market Gainers 5/30/13 2:24pm
Immunomedics Offers Progress of Antibody-Drug Conjugate Programs at NY Biotech Association Conference 5/30/13 8:36am
Immunomedics Reports Three New Patent Wins 5/7/13 8:34am
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors 4/10/13 8:32am
Immunomedics Announces First Results of Labetuzumab-SN-38 in Colorectal Cancer Study 4/9/13 8:34am
Immunomedics Settles FINRA Arbitration Proceedings, to Receive Gross Settlement of $18M 4/1/13 5:04pm
Stocks Hitting 52-Week Lows 2/22/13 11:18am
Algeta Initiates Research Program to Evaluate Potential of Targeted Thorium Conjugate Based on Immunomedics' Anti-Cd22 1/28/13 6:59am
more
Press Releases
Immunomedics to Present at Wells Fargo Securities 2013 Healthcare Conference 6/14/13 GlobeNewswire
Immunomedics Presents Epratuzumab's Mechanism of Action in Systemic Lupus Erythematosus 6/13/13 GlobeNewswire
Immunomedics Reports That UCB Announces New Results From Phase 2B Open-Label Extension Study Evaluating the Long-Term Effects of Epratuzumab in SLE 6/13/13 GlobeNewswire
Immunomedics Reports Progress With Labeling Proteins, Including Antibodies, for Improved PET Imaging 6/12/13 GlobeNewswire
Combination of 90Y-Epratuzumab and Veltuzumab is Active in Non-Hodgkin Lymphoma 6/11/13 GlobeNewswire
90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOP 6/10/13 GlobeNewswire
Immunomedics Develops Novel Dual System for Tumor Detection and Imaging 6/10/13 GlobeNewswire
New Data From Epratuzumab to be Presented at EULAR 2013 6/10/13 GlobeNewswire
Immunomedics Announces Six Presentations at the Society of Nuclear Medicine and Molecular Imaging 2013 Annual Meeting 6/3/13 GlobeNewswire
Immunomedics Presents Clinical Progress of Antibody-Drug Conjugate Programs at Conference of New York Biotechnology Association 5/30/13 GlobeNewswire
Immunomedics to Present at Jefferies 2013 Global Healthcare Conference 5/29/13 GlobeNewswire
Immunomedics Invents Method to Label Peptides and Other Proteins, Including Antibodies, With PET and MRI Imaging Radionuclides 5/28/13 GlobeNewswire

Get the latest IMMU stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Immunomedics, Inc. stock price.

Partner Headlines
Update on UCB Lupus Candidate - Analyst Blog 6/13/13
ALIOF Candidate Approved in Japan - Analyst Blog 2/20/13
Earnings Beat at Actelion - Analyst Blog 2/15/13
Immunomedics Inc. Reports Operating Results (10-Q) 2/9/13
These Small Cap Healthcare Stocks Could Move After Their Quarterly Check Up: HWAY, IMMU & MOH 2/6/13
Immunomedics Inc. Reports Operating Results (10-K) 8/24/12
Immunomedics Inc. Reports Operating Results (10-Q) 5/8/12
Immunomedics Inc. Reports Operating Results (10-Q) 2/8/12
UCB-Astellas Collaborate - Analyst Blog 2/7/12
CNS Cure Priority for UCB & Partner - Analyst Blog 1/13/12
UCB-Immunomedics Restructure Deal - Analyst Blog 1/5/12
Immunomedics Inc. Reports Operating Results (10-Q) 11/4/11